Latest Biotech News

Diagonal Therapeutics closed a $125 million Series B co‑led by Sanofi Ventures to advance DIAG723—its clustering antibody designed for hereditary hemorrhagic telangiectasia (HHT) and pulmonary...

Vizgen closed a $48 million financing led by Arch Venture Partners, M Ventures and Northpond Ventures to accelerate commercial growth, scale operations and push toward profitability. The company...

Eli Lilly agreed to acquire Ventyx Biosciences for about $1.2 billion in cash, securing clinical-stage NLRP3 inhibitors that Lilly says expand its inflammation franchise. The deal values Ventyx at...

Parabilis Medicines closed a $305 million Series F to accelerate development of its corkscrew-shaped peptide therapeutics, funding late-stage advancement of its lead oncology candidate. The...

EpiBiologics closed a $107 million Series B to advance its EpiTAC protein-degrading antibody platform into human testing, with GV and Johnson & Johnson’s venture arm leading the round. The Bay...

Alumis reported positive top-line results from two Phase III trials of envudeucitinib, a selective oral TYK2 inhibitor, meeting co-primary endpoints for skin clearance in moderate-to-severe plaque...

GSK and Ionis announced positive results from two pivotal Phase 3 trials of bepirovirsen, an antisense oligonucleotide for chronic hepatitis B, reporting functional cure rates that met primary...

Vizgen closed a $48 million financing round led by Arch Venture Partners, M Ventures and Northpond Ventures to scale commercial operations for its spatial transcriptomics platform, expand...

Pfizer and Gordian Bio struck a collaboration to apply Gordian’s in vivo mosaic screening platform to prioritize obesity targets directly within visceral adipose tissue. Gordian will run...

Sanofi signed a discovery and option collaboration with AI-driven Earendil Labs valued at up to $2.56 billion to use Earendil’s platform to identify bispecific antibody candidates for autoimmune...

Tessera Therapeutics plans to lay off 90 employees even as it prepares to initiate its first clinical study, according to internal documents. The move follows an organizational reshaping as the...

GSK and Helix struck a multi‑year collaboration giving GSK access to curated clinico‑genomic cohorts in Helix’s GenoSphere database to support precision‑medicine drug R&D. The arrangement includes...

Eli Lilly agreed to acquire Ventyx Biosciences for about $1.2 billion, adding clinical-stage oral NLRP3 inhibitors to its pipeline. The deal consolidates Lilly’s push into inflammation and...

GSK and development partner Ionis announced positive topline results from two pivotal Phase 3 trials of bepirovirsen, an antisense oligonucleotide aimed at inducing functional cure in chronic...

Alumis released top-line results from two Phase 3 trials showing envudeucitinib (an oral TYK2 inhibitor) met co-primary and key secondary endpoints in moderate-to-severe plaque psoriasis. The...

Amgen announced multiple Europe-focused oncology deals that together could be worth roughly $1.46 billion, including the acquisition of Dark Blue Therapeutics and a license pact with Disco...

Sanofi agreed a multi-year collaboration with AI-driven Earendil Labs to discover and develop bispecific antibodies for autoimmune and inflammatory diseases, a partnership valued at up to $2.56...

Arrowhead Pharmaceuticals published early clinical signals showing its RNAi candidates reduced visceral and liver fat when dosed in combination with Lilly’s tirzepatide (Zepbound). The company...

The U.S. Department of Health and Human Services and CDC revised the federal pediatric vaccine schedule, moving recommendations for six diseases from universal guidance to risk-based or shared...

A Nature paper described a gene therapy approach that targets cortical pain circuits to reproduce opioid-like analgesia without addiction in mouse models. Researchers used circuit-specific...